건선 치료시 Etretinate와 PUVA의 병용요법에 대한 임상적 고찰

Abstract

RePUVA therapy is the combination of an oral aromatic retinoid(Etretinate) with oral photochemotherapy(PUVA) for the treatment of psoriasis. This combination therapy has the advantage of faster clearance with fewer side effects. Thirty ambulatory psoriasis patients received RePUVA treatment. Etretinate was administered in a dosage of 0.75㎎/㎏ body weight, and PUVA was tried two times per week. Initial response of RePUVA therapy occured in patients with an average of 13.8±9.5 day, 6.0±2.8 irradiation and an accumulated ultraviolet A(UVA) dose of 6.8±4.8J/㎠. Clearance of lesion occured in 53% of patients with an average of 115.1±63.5day, 20.1±6.5 irradiation and an accumulated ultraviolet A(UVA) does of 38.9±17.7J/㎠. Side effects were occured in 27 patients. Dry skin & lip was most prominent side effect and erythematous pruritus, massive desquamation were followed. GI trouble, brittle nail, hair loss manifested, too.